Glofitamab with chemotherapy for newly diagnosed HIV-linked lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called glofitamab combined with standard chemotherapy (RCHOP) for people with HIV who have been newly diagnosed with a type of blood cancer called large B-cell lymphoma. The goal is to see if adding glofitamab helps fight the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV infection documented in your medical records
- You are taking HIV medications (antiretroviral therapy) that your doctor approves for this study
- You have been newly diagnosed with large B-cell lymphoma confirmed by biopsy
- Your cancer is stage II–IV and can be measured on scans or physical exam
- You are at least 18 years old and in reasonably good overall health (able to do light activities)
- Your blood counts, heart function, liver, and kidney function meet minimum requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests if adding a new targeted drug called glofitamab to standard chemotherapy works better than chemo alone for people with Burkitt lymphoma or double hit lymphoma. It may be a good option if you are newly diagnosed or if your lymphoma has come back after treatment.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests a drug called glofitamab (a type of immunotherapy) given as a follow-up treatment after initial therapy for people with high-risk large B-cell lymphoma. The goal is to see if it helps keep the cancer from coming back.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
Hear when a new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.